Skip to main content
Clinical Trials/NCT04332692
NCT04332692
Recruiting
Not Applicable

Acute Heart Failure - COngestion Discharge Evaluation. Évaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë.

Central Hospital, Nancy, France1 site in 1 country110 target enrollmentJuly 15, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Heart Failure
Sponsor
Central Hospital, Nancy, France
Enrollment
110
Locations
1
Primary Endpoint
Rate of all-cause death
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Acute heart failure (AHF) is a major public health problem, associated with a 40% risk of death or re-hospitalisation at 3 months. This risk is significantly increased by insufficient decongestion at the end of hospitalisation for AHF assessed by a standardised clinical score, a natriuretic peptide dosage or by cardiac and pulmonary ultrasound .

Adapting treatment according to lung congestion assessed by implantable devices (not reimbursed in France) improves the prognosis. However, due to the lack of a standardised congestion assessment, therapeutic adaptation in acute heart failure is currently empirical. The best multimodality approach to congestion evaluation is uncertain.

Registry
clinicaltrials.gov
Start Date
July 15, 2020
End Date
May 20, 2028
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Principal Investigator
Principal Investigator

Pr. Nicolas GIRERD

Principal Investigator

Central Hospital, Nancy, France

Eligibility Criteria

Inclusion Criteria

  • Patients hospitalised for acute heart failure.
  • Patients considered clinically discharging from hospitalisation for acute heart failure.
  • Age ≥18 years
  • Patients having received complete information regarding the study design and having signed their informed consent form.
  • Patient affiliated to or beneficiary of a social security scheme.

Exclusion Criteria

  • Comorbidity for which the life expectancy is ≤ 3 months
  • Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \<15 ml/min/m2 at inclusion.
  • History of lobectomy or pneumonectomy lung surgery
  • Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
  • Pregnant woman, parturient or nursing mother
  • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Adult person who is unable to give consent
  • Person deprived of liberty by a judicial or administrative decision,
  • Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.

Outcomes

Primary Outcomes

Rate of all-cause death

Time Frame: 3 months after hospital discharge

composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 2 and 3)

Rate of re-hospitalisation for acute heart failure

Time Frame: 3 months after hospital discharge

composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 1 and 3)

Rate of day-hospital or in-home IV diuretics injection for acute HF

Time Frame: 3 months after hospital discharge

composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 1 and 2)

Secondary Outcomes

  • Rate of all-cause death(3, 12 and 24 months after hospital discharge.)
  • NYHA (New York Heart Association) class measured(3, 12 and 24 months after hospital discharge)
  • Liver elastography value(At inclusion)
  • Renal function assessed by glomerular filtration rate(within 24 months after hospital discharge.)
  • Rate of day-hospital or in-home IV diuretics injection for acute HF(3, 12 and 24 months after hospital discharge.)
  • Rate of hospitalization for acute heart failure(3, 12 and 24 months after hospital discharge.)
  • Plasma volume(within 24 months after hospital discharge.)
  • Rate of re-hospitalisation for acute heart failure(12 and 24 months after hospital discharge)
  • Natriuretic peptides(within 24 months after hospital discharge.)
  • Quality of life(At inclusion and 3, 6 and 24 months)

Study Sites (1)

Loading locations...

Similar Trials